Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,122.23
(
-0.72%
)
US TECH 100
26,206.40
(
-1.37%
)
Dow Jones
49,182.59
(
-0.26%
)
Brent Oil
104.20
(
2.05%
)
Bitcoin
76,174.80
(
-1.55%
)
News Focus
News Focus
Post# of 30511
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122896
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 22898

Monday, 06/06/2022 3:26:53 AM

Monday, June 06, 2022 3:26:53 AM

Post# of 30511
CStone, PFE obtain China NMPA approval for PD-L1 agent, Cejemly (sugemalimab) in Stage III NSCLC; it was previously NMPA-approved in Stage IV (metastatic) NSCLC:

https://www.prnewswire.com/news-releases/cstone-and-pfizer-announce-nmpa-approval-of-sugemalimab-in-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer-301561552.html

Pursuant to a 2020 deal (#msg-158620042), PFE owns the commercial rights to Cejemly in Greater China and has a ~10% equity stake in CStone.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today